Progress of the pharmacokinetics of metformin in type 2 diabetes mellitus

Abstract

Abstract: Pharmacogenetics indicates that genetic polymorphisms of drug metabolizing enzymes, receptors, and transporter are the major causes for individual difference in drug response. Metformin is regarded as insulin sensitizing drugs and the first-line agent for type 2 diabetes mellitus (T2DM) patients with overweight or obesity. Metformin is also used for treatment polycystic ovary syndrome (PCO_S). Considerable individual differences in metformin efficacy are reported. Organic cation transporters (OCT_S) play the important roles in the individual difference of metformin response rather than drug metabolizing enzymes and drug receptors. Thus we reviews the effects of the polymorphisms of OCT_S on metformin response and the progress of the pharmacokinetics of metformin in T2DM.

Key words: Metformin, Pharmacogenetics, OCT_S, Metformin response, Genetic polymorphisms

CLC Number:

R968

DONG Min, LIU Zhao-qian. Progress of the pharmacokinetics of metformin in type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1315-1320.

References

[1] Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030[J]. Diabetes Care, 2004, 27(10): 1047-1053.
[2] Bailey CJ, Turner RC. Metformin[J]. N Engl J Med, 1996, 334(9): 574-579.
[3] Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update[J]. Ann Intern Med, 2002, 137(1): 25-33.
[4] Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome[J]. Eur J Endocrinol, 138(3): 269-274.
[5] Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus[J]. N Engl J Med, 1995, 333(9): 550-554.
[6] Dominguez LJ, Davidoff AJ, Srinivas PR, et al. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle[J]. Endocrinology, 1996, 137(1): 113-121.
[7] Matthaei S, Hamann A, Klein HH, et al. Association of metformin's effect to increase insulin- stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes[J]. Diabetes, 1991, 40(7): 850-857.
[8] Hundal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells[J]. Endocrinology, 1992, 131(3): 1165-1173.
[9] Sambol NC, Chiang J. Pharmacokinetics and pharmacodynamics of metformin on healthy subjects with noninsulin-dependent diabetes mellitus[J]. J Clin Pharmacol, 1996, 36(11): 1012-1021.
[10] Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1[J]. Drug Metab Pharmacokinet, 2005, 20(5): 379-386.
[11] Dresser MJ, Xiao G, Leabman MK, et al. Interactions of N-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2)[J]. Pharm Res, 2002, 19(8): 1244- 1247.
[12] Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication [J]. Eur J Clin Invest, 2003, 33(12): 17-22.
[13] Campbell IW. Management of type 2 diabetes mellitus with special reference to metformin therapy [J]. Diabetes Metab, 1991, 17(1/2): 191-196.
[14] Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)[J]. JAMA, 1999, 281(121): 2005-2012.
[15] Ieiri I, Takane H, Hirota T, et al. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy[J]. Expert Opin Drug Metab Toxicol, 2006, 2(5): 651-674.
[16] Sogame Y, Kitamura A, Yabuki M, et al. A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes[J]. Biopharm Drug Dispos, 2009, 30(8): 476-484.
[17] Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update[J]. AIDS, 2005, 19(5): 455-462.
[18] Fukushima-Uesaka H, Maekawa K, Ozawa S, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2)[J]. Drug Metab Pharmaco- kinet, 2004, 19(3): 239-244.
[19] Nies AT, Koepsell H, Winter S, et al. Expression of organic cation trans-porters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by geneticfactors and cholestasis in human liver[J]. Hepatology, 2009, 50(4): 1227-1240.
[20] Koepsell H, Endou H. The SLC22 drug transporter family[J]. Eur J Physiol, 2004, 447(5): 666-676.
[21] Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1[J]. Proc Natl Acad Sci USA, 2003, 100(10): 5902-5907.
[22] Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics[J]. Clin Pharmacol Ther, 2007, 83(2): 273-280.
[23] Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action[J]. J Clin Invest, 2007, 117(5): 1422-1431.
[24] Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions[J]. Biochem Biophys Res Commun, 2004, 313(3): 789-793.
[25] Takane H, Shikata E, Otsubo K, et al. Polymorphism in human organic cation transporters and metformin action[J]. Pharmacogenomics, 2008, 9(4): 415-422.
[26] Itoda M, Saito Y, Maekawa K, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1)[J]. Drug Metab Pharmacokine, 2004, 19(4): 308-312.
[27] Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin[J]. Pharmacogenet Genomics, 2009, 19(4): 497-504.
[28] Zolk O, Solbach TF, Konig J, et al. Structural determinants of inhibitorinteraction with the human organic cation transporter OCT2 (SLC22A2)[J]. Naunyn Schmiedebergs Arch Pharmacol, 2009, 379(4): 337-348.
[29] Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance[J]. Pharmacogenetics, 2003, 13(9): 581-584.
[30] Song I, Shin H, Shim E, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin[J]. Clin Pharmacol Ther, 2008, 84(5): 559-562.
[31] Wang Z, Yin O, Chow M. OCT2 polymorphism in vivo renal functional consequence: studies with metformin and cimetidine[J]. Clin Pharmacol Ther, 2007, 18(7): 637-645.
[32] Legro RS, Barnhart HX, Schlaff WD, et al. Ovulatory Response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene[J]. J Clin Endocrinol Metab Doi, 2008, 93(3): 792-800.
[33] Ertunc D, Tok EC, Aktas A, et al. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome[J]. Hum Reprod, 2005, 20(5): 1207-1212.